# EDGAR Filing Document

**Accession Number:** 0001223348
**File Stem:** 0001209191-23-018460
**Filing Date:** 2023-3
**Character Count:** 8313
**Document Hash:** 674558fb4e0d312c8908214f6329fe16
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-018460.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001209191-23-018460

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** WAGNER CHARLES F JR
- **CENTRAL INDEX KEY:** 0001223348

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19319
- **FILM NUMBER:** 23731320

**MAIL ADDRESS:**
- **STREET 1:** C/O MILLIPORE CORP
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01820
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERTEX PHARMACEUTICALS INC / MA
- **CENTRAL INDEX KEY:** 0000875320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 043039129
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6173416393

**MAIL ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>WAGNER CHARLES F JR<br><sub>(Last) (First) (Middle)</sub><br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>50 NORTHERN AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP & Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERTEX PHARMACEUTICALS INC / MA [ VRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 361 | D | 286.64<sup>(2)(3)</sup> | 57772 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 515 | D | 287.83<sup>(2)(4)</sup> | 57257 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 327 | D | 288.91<sup>(2)(5)</sup> | 56930 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 30 | D | $289.44 | 56900 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 541 | D | 291.47<sup>(2)(6)</sup> | 56359 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 185 | D | 292.68<sup>(2)(7)</sup> | 56174 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 27 | D | $293.61 | 56147 | D |  |
| Common Stock | 2023-03-10 |  | S<sup>(1)</sup> |  | 102 | D | 294.94<sup>(2)(8)</sup> | 56045 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 24 | D | $288.31 | 56021 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 420 | D | 292.41<sup>(2)(9)</sup> | 55061 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 1153 | D | 293.35<sup>(2)(10)</sup> | 54448 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 715 | D | 294.52<sup>(2)(11)</sup> | 53733 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 292 | D | 295.89<sup>(2)(12)</sup> | 53441 | D |  |
| Common Stock | 2023-03-13 |  | S<sup>(1)</sup> |  | 62 | D | $296.77 | 53379 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1.

(2) Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(3) Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16).

(4) Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20).

(5) Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34).

(6) Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00).

(7) Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12).

(8) Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35).

(9) Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82).

(10) Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80).

(11) Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81).

(12) Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32).

**Signature:** /s/ Christiana Stevenson, Attorney-in-Fact  
**Date:** 2023-03-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**